Hope emerging in the locally advanced cervical cancer landscape
- PMID: 39288780
- DOI: 10.1016/S0140-6736(24)01918-4
Hope emerging in the locally advanced cervical cancer landscape
Conflict of interest statement
I took part in an advisory board and in a health economics interview regarding the progression-free survival data from the ENGOT-cx11/GOG-3047/KEYNOTE-A18 study previously published,(7) but was not involved in the current Article.(3) I report grants from AstraZeneca, Deciphera, and GSK; consulting fees from GSK, Ipsen, and MSD; speakers fees from AstraZeneca, BMS, GSK, Ipsen, MSD, Pfizer, and Pharmamar; support for meetings or travel from AstraZeneca, GSK, Ipsen, MSD, Pfizer, and Pharmamar; and participation on data safety monitoring board or advisory boards for AstraZeneca, BMS, Eisai, GSK, Ipsen, and MSD.
Comment on
-
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2024 Oct 5;404(10460):1321-1332. doi: 10.1016/S0140-6736(24)01808-7. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288779 Clinical Trial.
